The news is directly about Vertex Pharmaceuticals. The 'Sector Perform' rating suggests that the analyst expects the stock to perform in line with the sector average. The increase in price target could be seen as a positive signal, but it's a minor increase and the overall rating hasn't changed, so the impact on the stock price is likely to be neutral in the short term.